Novo Nordisk unveils Wegovy sales
Friday, pharmaceutical firm Novo Nordisk has publicized its quarterly report, in which the company reveals for the very first time exact sales figures for obesity drug Wegovy, beating analysts’ best bets by far.
by christopher due karlsson, translated by daniel pedersen
Since launching obesity treatment Wegovy on the US market in June of last year, Novo Nordisk has not wanted to report on individual sales within its Obesity Care business.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk subsupplier reinitiates Wegovy production
For subscribers
Novo Nordisk more than doubles 2025 obesity sales goal
For subscribers
Novo CFO: Obesity market is difficult to predict
For subscribers
